MF
MLYS icon

Magnetar Financial’s Mineralys Therapeutics MLYS Stock Holding History

Magnetar Financial’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$502K Buy
+18,549
New +$544K 0.01% 628

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Magnetar Financial's MLYS Position: Q1 2026 in Review

Magnetar Financial opened a new position in Mineralys Therapeutics (MLYS) in Q1 2026: 18,549 shares worth $502K. The stake represents 0.01% of the portfolio and ranks #628 among its holdings.

214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Magnetar Financial held 18,549 shares of Mineralys Therapeutics worth $502K as of Q1 2026.
  • Mineralys Therapeutics was a new Magnetar Financial position in Q1 2026.
  • Mineralys Therapeutics made up 0.01% of Magnetar Financial's portfolio in Q1 2026, its #628 holding.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Magnetar Financial's 13F filing for Q1 2026, filed 13 May 2026.